Document ID: chunk:federal_register_of_legislation:F2025C00183:clause:1_71153
Version: federal_register_of_legislation:F2025C00183
Segment Type: clause
Provision Reference: sch 1 cl 71153
Character Range: 222373–223750

71153                Testing, for assessment or diagnosis of systemic inflammatory disease or vasculitis, for the presence of an antibody:                                                                                                                                                                                                                                                                                                                                                                          34.55
                     (a) by one of the following tests:
                     (i) antineutrophil cytoplasmic antibody (ANCA) immunofluorescence test;
                     (ii) antineutrophil proteinase 3 antibody (PR3 ANCA) test;
                     (iii) antimyeloperoxidase antibody (MPO ANCA) test;
                     (iv) antiglomerular basement membrane antibody (GBM ANCA) test; or
                     (b) by either or both of the tests mentioned in subparagraphs (a)(ii) and (iii), if a test mentioned in subparagraph (a)(i) was requested and:
                     (i) the result is abnormal; or
                     (ii) a test mentioned in subparagraph (a)(i) has previously been carried out and the result was abnormal; or
                     (iii) either or both of the antibodies mentioned in subparagraphs (a)(ii) and (iii) have been previously detected